Rigel Pharmaceuticals (RIGL) PT Lowered to $7 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Gary Nachman lowered the price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $7.00 (from $8.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
